​

Plus Therapeutics (PSTV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PSTV Stock Forecast

Plus Therapeutics (PSTV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $1.00, with a high of $1.00 and a low of $1.00. This represents a 244.83% increase from the last price of $0.29.

High: $1 Avg: $1 Low: $1 Last Closed Price: $0.29

PSTV Stock Rating

Plus Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

PSTV Price Target Upside V Benchmarks

TypeNameUpside
StockPlus Therapeutics244.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$1.00$1.50
Last Closing Price$0.29$0.29$0.29
Upside/Downside-244.83%417.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2614---5
Feb, 2613---4
Jan, 2613---4
Dec, 2513---4
Nov, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 23, 2026Sean LeeH.C. Wainwright$1.00$0.29244.83%244.83%
Nov 26, 2025Sean LeeH.C. Wainwright$2.00$0.61227.87%589.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 03, 2026Lake StreetBuyinitialise
Jan 23, 2026H.C. WainwrightBuyBuyhold
Nov 26, 2025H.C. WainwrightBuyBuyhold
Nov 03, 2025H.C. WainwrightBuyBuyhold
Nov 15, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024AscendiantBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-11.55$-4.24$-1.95$-0.29---
Avg Forecast$-11.06$-4.63$-1.94$-1.49$-1.51$-1.08$0.34
High Forecast$-9.20$-4.19$-1.75$-1.44$-0.72$-0.06$0.37
Low Forecast$-12.67$-5.07$-2.12$-1.53$-2.46$-1.97$0.30
Surprise %4.43%-8.42%0.52%-80.54%---

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$224.00K$4.91M$5.82M----
Avg Forecast$1.35M$4.66M$6.36M$4.80M$16.86M$31.09M$73.91M
High Forecast$1.50M$5.00M$6.69M$5.15M$18.08M$33.34M$79.25M
Low Forecast$1.17M$4.32M$6.01M$4.44M$15.62M$28.79M$68.44M
Surprise %-83.40%5.36%-8.37%----

Net Income Forecast

$-40M $-31M $-22M $-13M $-4M $5M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-20.27M$-13.32M$-12.98M$-22.39M---
Avg Forecast$-34.75M$-13.32M$-6.07M$-4.67M$-4.99M$-3.20M$1.06M
High Forecast$-28.89M$-13.15M$-5.49M$-4.53M$-2.27M$-199.80K$1.16M
Low Forecast$-39.79M$-15.92M$-6.65M$-4.80M$-7.72M$-6.19M$955.63K
Surprise %-41.65%-113.79%379.83%---

PSTV Forecast FAQ

Is Plus Therapeutics stock a buy?

Plus Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Plus Therapeutics is a favorable investment for most analysts.

What is Plus Therapeutics's price target?

Plus Therapeutics's price target, set by 4 Wall Street analysts, averages $1 over the next 12 months. The price target range spans from $1 at the low end to $1 at the high end, suggesting a potential 244.83% change from the previous closing price of $0.29.

How does Plus Therapeutics stock forecast compare to its benchmarks?

Plus Therapeutics's stock forecast shows a 244.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Plus Therapeutics over the past three months?

  • March 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Plus Therapeutics’s EPS forecast?

Plus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.51, marking a 420.69% increase from the reported $-0.29 in 2025. Estimates for the following years are $-1.08 in 2027, and $0.34 in 2028.

What is Plus Therapeutics’s revenue forecast?

Plus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $16.86M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $31.09M, and $73.91M for 2028.

What is Plus Therapeutics’s net income forecast?

Plus Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-4.991M, representing a -77.71% decrease from the reported $-22.386M in 2025. Projections indicate $-3.197M in 2027, and $1.06M in 2028.